ARWR insider trading
NasdaqGS HealthcareARROWHEAD PHARMACEUTICALS, INC.: insider trade history from SEC Form 4 filings.
About ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Company website: arrowheadpharma.com
ARWR insider activity at a glance
FilingIQ tracks 658 insider transactions for ARWR in filings since Jan 7, 2015. The most recent transaction is dated Aug 18, 2026.
Across the full history, 16 open-market purchases
and 397 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ARWR insider trades is 59.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ARWR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding ARWR
Frequently asked
- How many insider trades does FilingIQ track for ARWR?
- FilingIQ tracks 658 Form 4 insider transactions for ARWR (ARROWHEAD PHARMACEUTICALS, INC.), covering filings from Jan 7, 2015 onwards. 2 of those are dated within the last 90 days.
- Are ARWR insiders net buyers or net sellers?
- Across the full Form 4 history for ARWR, 16 transactions (2%) were open-market purchases and 397 (60%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ARWR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ARWR in?
- ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.93B.
Methodology & sources
Every ARWR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.